The US Food and Drug Administration’s biosimilar approvals appear to be the agency operation that is suffering the most under the strain of the coronavirus pandemic, but the FDA argues the drop in on-time actions is a function of the program’s relatively small sample size, not an inherent performance problem.
But with review timeliness also slipping a bit for the prescription and generic drug user fee programs over the last...








